A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Xentuzumab (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 10 Jun 2017 Biomarkers information updated
- 20 Feb 2017 Planned End Date changed from 1 Apr 2018 to 1 Aug 2017.
- 09 Jan 2017 Status changed from recruiting to active, no longer recruiting.